All In Biotech

Drug Trial Radar · NCT05198505

Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors

Phase I Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQB2868 Injection in Subjects With Advanced Malignant Tumors

Last checked: Nov 20, 2026Latest source record: May 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

280

Planned (sponsor's estimate)

Start

Apr 27, 2022

Primary completion

Jun 2023

Study completion Jun 2024

Sponsor

Sponsor type
Industry
First posted
Jan 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The TQB2868 protein in this study targeted programmed cell death protein 1 (PD-1) and transforming growth factor-β (TGF-β). The bifunctional fusion protein targets and neutralizes TGF-β in the tumor microenvironment. On the basis of inhibiting PD-1 / programmed death ligand 1 (PD-L1) pathway, T cells can restore activity, enhance immune response, and more effectively improve the effect of inhibiting tumor occurrence and development.

Conditions

  • Advanced Malignant Tumor

Interventions

  • TQB2868 InjectionDrug

    TQB2868 protein is a bi-functional fusion protein targeting PD-1 and TGF-β

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicity (DLT)Time frame: up to 10 months
  2. Recommended Phase II Dose (RP2D)Time frame: up to 10 months
  3. Maximum Tolerated Dose (MTD)Time frame: up to 10 months
  4. All adverse events (AE), serious adverse events (SAE), and treatment-related adverse events (TEAEs)Time frame: up to 17 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Linyi Cancer Hospital

    Linyi, Shandong, China · Recruiting

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.